The Prostate Cancer Demon

News
Article

My prostate cancer has come back and stronger, but so have I.

Image of a doctor showing his patient images on a tablet.

The Demon

I’ll face the demon,

I thought I beat years ago.

You’re back and stronger this time,

but so am I, so am I.

I wasn’t looking for this fight,

I was happy without you.

But you forced your way

back into my life

More doctors, more oncologists,

more blood drawn,

more drugs.

All looking to beat you.

So bring it on, let’s go!

I have an army behind me,

Doctors, family and friends

I’m ready for you.

This post was written and submitted by Peter O'Connor. The article reflects the views of O'Connor and not of CURE®. This is also not supposed to be intended as medical advice.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Reginald Tucker-Seeley, MA, ScM, ScD, an expert on prostate cancer
Alicia Morgans, MD, MPH, an expert on prostate cancer
Reginald Tucker-Seeley, MA, ScM, ScD, an expert on prostate cancer
Rashid K. Sayyid, MD, MSc, an expert on prostate cancer
Rashid K. Sayyid, MD, MSc, an expert on prostate cancer
Rashid K. Sayyid, MD, MSc, an expert on prostate cancer
Rashid K. Sayyid, MD, MSc, an expert on prostate cancer
Alicia Morgans, MD, MPH, an expert on prostate cancer
Alicia Morgans, MD, MPH, an expert on prostate cancer
Rashid K. Sayyid, MD, MSc, an expert on prostate cancer
Related Content
Image of FDA approval, what you need to know.

Enhertu Marks First Therapy Approved Across HER2-Positive Solid Tumors

April 24th 2024
Article

Treatment with Enhertu “is an unprecedented approval” for patients with HER2-positive solid tumors who did not have many options, an expert told CURE®.

Read More

Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

January 30th 2024
Podcast

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.

Listen

Image of a doctor holding an image of a bladder.

Padcev-Keytruda Combo Nearly Doubles Survival Time in Bladder Cancer

April 19th 2024
Article

The survival benefit observed with Padcev plus Keytruda was “unlike anything we’d seen before” for advanced bladder cancer, according to an expert.

Read More

CURE Cancer Horizons podcast logo

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

January 29th 2024
Podcast

CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.

Listen

Image of prostate cancer.

ADC FG-3246 May Show Promise in Advanced Prostate Cancer

April 18th 2024
Article

Topline data has been released from a trial of antibody-drug conjugate FG-3246 for patients with pretreated, metastatic castration-resistant prostate cancer.

Read More

Image of a doctor holding a graphic of kidneys.

Postsurgical Keytruda Improves Survival in Clear Cell Kidney Cancer

April 18th 2024
Article

For decades, researchers have been seeking a therapy to improve outcomes for patients with clear cell renal cell carcinoma who underwent a nephrectomy.

Read More